Tuberculosis is one of the 10 leading reasons for death on the earth. Tuberculosis is an airborne bacterial contamination brought by M. tuberculosis which influences any aspect of the body and most normally the lungs. M. tuberculosis has waxy covering on its cell surface basically because of the presence of mycolic acid. As of late, a few mycobacterial species, including M. tuberculosis, have been found to shape drug-tolerant biofilms in vitro through hereditarily controlled mechanisms. Bacterial biofilms are serious worldwide wellbeing worry because of their capacities to tolerate antibiotics, host defence systems. M. tuberculosis needs cholesterol to taint and get by inside the host. Host-directed therapies are a moderately new and promising way to deal with treatment of tuberculosis. Statins are inhibitors of HMG-CoA reductase, a rate-limiting enzyme of the cholesterol biosynthesis pathway, which catalyzes transformation of HMG-CoA reductase into mevalonate and have pleiotropic impacts, including wide reach immunomodulatory, anti-inflammatory and antimicrobial effects. It has been accounted that cells treated with statins are more resistant to M. tuberculosis disease. The point of this review to assemble the accessible logical information on the biofim development by Mycobacteria tuberculosis and impact of statins on M. tuberculosis and biofilms of microorganisms.
Article Details
Unique Paper ID: 150390
Publication Volume & Issue: Volume 7, Issue 5
Page(s): 149 - 159
Article Preview & Download
Share This Article
Conference Alert
NCSST-2023
AICTE Sponsored National Conference on Smart Systems and Technologies
Last Date: 25th November 2023
SWEC- Management
LATEST INNOVATION’S AND FUTURE TRENDS IN MANAGEMENT